Socio-Economic Implications for the UK The potential for retatrutide to reduce the prevalence of obesity-related conditionssuch as the 42 identified conditions including cancer, cardiovascular disease, and strokecould lead to significant savings for the UK economy
10.1097/00003086-199305000-00038 59 KawakamiT.KawaiT.TakeiN.KiseT.EdaS.UristM
Additional information Peer review information Nature Communications thanks Radostin Danev, Kyle Sloop and other, anonymous, reviewers for their contributions to the peer review of this work
Box 1: Recent Trump Administration Obesity Drug Initiatives In November 2025, the Trump administration announced reaching a deal with Eli Lilly and Novo Nordisk to lower the cost of their GLP-1s for Medicare, Medicaid, and those purchasing the drugs directly from the manufacturers through a new TrumpRx website
In their recent study, Cardia et al
,